Japan's Kirin, Kyowa Merge To Strengthen Biotechnology Focus
This article was originally published in PharmAsia News
Executive Summary
Kirin Holdings and Kyowa Hakko will seek to bring together each company's strength in biotech to create a global research and development-centered Japanese drug company. The two Tokyo-based companies announced a merger agreement Oct. 22, reflecting the ongoing consolidation of the Japanese drug industry
You may also be interested in...
Kirin Pharma Exec Tamao Watanabe On U.S. Biotech-Japan Pharma Collaborations: An Interview With PharmAsia News (Part 2 of 2)
Painstaking communication efforts, including putting plans in writing to overcome a language gap, are keys to Kirin’s partnership with Argos.
Kirin Pharma Exec Tamao Watanabe On U.S. Biotech-Japan Pharma Collaborations: An Interview With PharmAsia News (Part 2 of 2)
Painstaking communication efforts, including putting plans in writing to overcome a language gap, are keys to Kirin’s partnership with Argos.
Kirin Pharma Exec Tamao Watanabe On U.S. Biotech-Japan Pharma Collaborations: An Interview with PharmAsia News (Part 2 of 2)
Tokyo-based Kirin Pharma, which plans to merge with Kyowa Hakko Oct. 1, has done some 35 partnerships since parent company Kirin Brewery entered the pharmaceutical business in 1982. Tamao Watanabe, Kirin Pharma's senior manager of business development for the licensing section in the business development department, recently sat down with PharmAsia News' Tokyo bureau to talk about its partnership with North Carolina-based biotech venture Argos Therapeutics and how to make Japan-Western biotech partnerships work.